There are 410 resources available
46P - Multi-center, phase II study of docetaxel (DTX) plus ramucirumab (RAM) following platinum-based chemotherapy plus ICIs in patients with NSCLC: SCORPION study
Presenter: Reiko Matsuzawa
Session: Poster Display session
47P - Timing of radiotherapy affects outcomes of patients with metastatic NSCLC who receive immunotherapy
Presenter: Shenduo Li
Session: Poster Display session
48P - Characteristics and treatment patterns of patients with advanced or metastatic non-small cell lung cancer managed with first-line immuno-oncology strategies in Greece: Interim results of a real-world prospective study (IO-HORIZON)
Presenter: Helena Linardou
Session: Poster Display session
49P - Patient-reported outcomes (PROs) in patients with advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% receiving cemiplimab (CEMI) monotherapy vs chemotherapy (CHEMO): EMPOWER-Lung 1 liver metastases subpopulation
Presenter: Ana Baramidze
Session: Poster Display session
50P - Patient-reported outcomes in non-small cell lung cancer patients receiving immunotherapy monotherapy: Analysis from enhanced, EHR-facilitated cancer symptom control (E2C2) pragmatic clinical trial
Presenter: Bolun Liu
Session: Poster Display session
51P - Real-word outcomes of immunotherapy in non-small cell lung cancer: A population-based cohort study in Sweden
Presenter: Lars Gunnar Wagenius
Session: Poster Display session
52P - Real-world versus clinical trial outcomes of pembrolizumab plus chemotherapy in patients with stage IV non-squamous non-small cell lung cancer
Presenter: Marjon Verschueren
Session: Poster Display session
53P - Real-world outcomes of first-line pembrolizumab (Pem) for metastatic non-small cell lung cancer (mNSCLC) with ≥50% expression of programmed cell death-ligand 1 (PD-L1): A multicentre retrospective study
Presenter: Javier Perea
Session: Poster Display session
54P - Real-world efficacy of immunotherapy plus anti-angiogenesis versus immunotherapy monotherapy as second-line or later treatment in advanced non-small cell lung cancer
Presenter: Yao Zhang
Session: Poster Display session
55P - Real-world monitoring of hybrid dosing of pembrolizumab in stage IV non-small cell lung cancer in the Netherlands
Presenter: Esther Dronkers
Session: Poster Display session